Cell Medica Limited and University College London (UCL) have entered a research collaboration agreement to develop leading-edge modified T-cell receptor (TCR) products for the treatment of cancer.

According to the agreement, Cell Medica will fund all research and development activities with an exclusive option to license all products developed in collaboration, whereas UCL will be responsible to conduct all pre-clinical and early clinical research under the guidance of a joint steering committee.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The agreement enables Cell Medica to develop breakthrough treatments for cancer using cellular immunotherapy products.

Biopharmaceutical company Cloaked Therapeutics has entered a co-development agreement with Monvida Pharmaceuticals, a pharmaceutical company, to develop TumorSelect Paclitaxel® for all oncology indications.

According to the agreement, Monvida Pharma will be responsible for developmental and commercialisation rights in China and Vietnam, while Cloaked Therapeutics will be responsible for the developmental and commercialisation rights in all other world markets.

The agreement enables the two partners to provide improved cancer care in China and Vietnam markets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SynCore Biotech has announced a rights offering of 9.2m shares of its common stock to raise gross proceeds of $8.67m.

The company plans to use the funds to advance the development of new drugs.

Genetic testing company Singlera Genomics has raised $20m in a series A venture financing round.

The company plans to invest the funds to further advance the development and commercialisation of its genomic sequencing tests for cancer and other genetic diseases.

"Genetic testing company Singlera Genomics has raised $20m in a series A venture financing round."

Sophiris Bio has priced the underwritten public offering of 6.5m shares of its common stock.

Piper Jaffray & Co. is acting as sole book-running manager and Maxim Group LLC is acting as co-manager, while Cooley LLP is acting as legal advisor for the offering.

The company expects to raise gross proceeds of approximately $26m from the offering.

The clinical-stage biopharmaceutical company plans to use the proceeds to fund clinical trials and develop topsalysin, as well as for research and development (R&D), general corporate and administrative purposes.

Image: Cell Medica Limited and University College London (UCL) have entered a research collaboration agreement. Photo: Courtesy of Stevecadman.